Results
1 -
8 of
8Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3-C-ethynyl-??-D-ribo-pentofuranosyl)cytosine and 1-(3-C-ethynyl-??-D-ribo-pentofuranosyl)uracil, Cancer Chemotherapy and Pharmacology Effect of duplex drugs linking 2u2032-deoxy-5-fluorouridine (5-FdU) with 3u2032-C-ethynylcytidine (ECyd) on hepatoblastoma cell lines, Pediatric Surgery International Role of RNase L in apoptosis induced by 1-(3-C-ethynyl-??-d-ribo-pentofuranosyl)cytosine, Cancer Chemotherapy and Pharmacology Phase I and pharmacokinetic study of 3u2032-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies, Investigational New Drugs A nucleoside anticancer drug, 1-(3-C-ethynyl-??-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression, Molecular Cancer RNA polymerase III transcription in cancer: the BRF2 connection, Molecular Cancer The basal transcription machinery as a target for cancer therapy, Cancer Cell International 3'-Ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction, BMC Cancer